Imunon, Inc. (IMNN)
| Market Cap | 7.52M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.64M |
| Shares Out | 4.20M |
| EPS (ttm) | -4.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 72,525 |
| Open | 1.730 |
| Previous Close | 1.720 |
| Day's Range | 1.710 - 1.845 |
| 52-Week Range | 1.700 - 11.191 |
| Beta | 1.93 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+849.72%) |
| Earnings Date | Aug 4, 2026 |
About IMNN
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develo... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for IMNN stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 849.72% from the latest price.
News
Imunon Transcript: Life Sciences Virtual Investor Forum
A novel IL-12 DNA-based immunotherapy for ovarian cancer is showing unprecedented survival benefits in phase II, with a favorable safety profile and strong FDA alignment. The phase III trial is ahead of enrollment targets, and interim analyses may enable early approval.
Imunon Slides: Life Sciences Virtual Investor Forum
Imunon has posted slides in relation to its latest quarterly earnings report, which was published on June 25, 2026.
Imunon announces IDMC recommendation for continuation of OVATION 3 trial
Imunon (IMNN) announced that the independent Data Monitoring Committee, or IDMC, has recommended continuation of the pivotal Phase 3 OVATION 3 clinical trial evaluating IMNN-001 in combination with st...
IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer No...
IMUNON to Present at the Life Sciences Investor Forum on June 25th
LAWRENCEVILLE, N.J., June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lin...
Imunon Transcript: AGM 2026
The meeting highlighted strong clinical progress for IMNN-001, robust financial management, and approval of all shareholder proposals, including director elections and compensation. No questions were raised, and the company remains focused on advancing its lead therapy.
IMUNON Announces Up to $10 Million Cash Financing
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports IMUNON's Highly Anticipated Phase 3 OVATI...
Imunon reports Q1 EPS (84c), consensus ($1.28)
“Enrollment in our pivotal Phase 3 OVATION 3 trial continues ahead of plan, reflecting patient interest and strong conviction among principal investigators and the broader medical community in IMNN-00...
Imunon Earnings Call Transcript: Q1 2026
Phase III OVATION 3 trial enrollment is ahead of schedule, with strong clinical data and investigator enthusiasm supporting IMNN-001's potential in ovarian cancer. Financial discipline and creative financing strategies are extending the cash runway, while positive FDA engagement and a robust R&D pipeline position the company for key milestones in 2026 and beyond.
Imunon Earnings release: Q1 2026
Imunon released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Imunon Quarterly report: Q1 2026
Imunon has published its Q1 2026 quarterly earnings report on May 12, 2026.
IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update
IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment i...
IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026
LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company w...
Imunon Proxy statement: Proxy filing
Imunon filed a proxy statement on May 4, 2026, providing details for shareholder voting and corporate governance matters.
Imunon initiated with a Buy at Maxim
Maxim initiated coverage of Imunon (IMNN) with a Buy rating and $10 price target
Imunon Earnings Call Transcript: Q4 2025
IMNN-001 immunotherapy showed a 14.7-month median overall survival benefit in Phase II, fueling rapid Phase III enrollment and strong clinical interest. Cash runway extends into late 2026, with disciplined cost management and ongoing partnership and financing efforts.
Imunon Annual report: Q4 2025
Imunon has published its Q4 2025 annual report on March 31, 2026.
Imunon Earnings release: Q4 2025
Imunon released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clin...
Imunon announces final clinical data from OVATION 2 clinical trial
Imunon (IMNN) announced final clinical data from the completed Phase 2 OVATION 2 clinical trial evaluating IMNN-001 in combination with standard of care neoadjuvant and adjuvant chemotherapy. The larg...
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysis Patients tre...
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Comp...
Imunon announces reorganization to eliminate headcount for Phase 3 trial
Imunon (IMNN) announced a strategic reorganization that will eliminate headcount not essential to the Phase 3 trial and redefine the job descriptions for additional employees to reduce operating expen...
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the c...
Imunon prices 1.94M shares at $3.61 in registered direct offering
IMUNON (IMNN) entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 1,939,114 shares of common stock, together with warrants...